A major challenge faced in the field of biologics drug discovery is the long and labor-intensive workflows needed for identification and validation of potential therapeutics.
Creoptix, a Malvern Panalytical brand, has developed the WAVEsystem to support scientists in life sciences to accelerate drug discovery. The grating-coupled interferometry (GCI) detection principle provides a stable signal, ideal for measuring tight binding interactions. In combination with no-clog WAVEchips and waveRAPID (a new method of measuring kinetics from single well), the Creoptix® WAVEsystem can substantially shorten and/or combine different steps in the workflow.
In this webinar, Amanda Poon, Application Scientist at Malvern Panalytical, working for Creoptix, and Dr. Wu Danqing, Director of Biologics Discovery at EpimAb Biotherapeutics, will discuss how the WAVEsystem supports biologics research by allowing you to measure high-quality binding affinity and kinetics in complex samples.
Speakers
- Amanda Poon - Application Scientist Creoptix WAVEsystem, Malvern Panalytical
- Dr. Wu Danqing - Director of Biologics Discovery, EpimAb Biotherapeutics
- Blake Forman - SelectScience
More information
What will you learn?
- Learn the importance of reliable molecular binding characterization, including binding kinetics, in antibody development
- Understand how the WAVEsystem combines high sensitivity and signal stability with crude sample compatibility and throughput to accelerate your biologics development
- Discover how no-clog microfluidics allows you to measure binding kinetics in complex samples (serum, cell lysates and more) with less device downtime
Who should attend?
- Anyone interested in measuring binding kinetics and affinity in biologics and other complex matrices
- Research and development scientists interested in biologic drug development
- Scientists interested in diagnostics development
- Researchers facing challenges on tight binders (pM) in unpurified samples
- Anyone interested in antibody research and development